2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 879

Diffuse Alveolar Hemorrhage Secondary to ANCA-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes
Abstract Number: 1728

Diffusion Weighted Imaging Is a Sensitive and Specific MRI Protocol for the Diagnosis and Assessment of Disease Severity in Ankylosing Spondylitis
Abstract Number: 359

Diminished Health-Related Quality of Life As Measured By the Short Form-10 in Children with Hypophosphatasia
Abstract Number: 2297

Dinamyx Neuromodulation in Fibromyalgia
Abstract Number: 789

Direct Coombs Positivity in SLE
Abstract Number: 65

Disability in the Rheumatic Diseases
Abstract Number: 2863

Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Abstract Number: 2007

Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis
Abstract Number: 1248

Discovery of Novel Serum Biomarkers for Osteoarthritis Using Affinity Proteomics
Abstract Number: 1671

Discovery of PRN1008, a Novel, Reversible Covalent BTK Inhibitor in Clinical Development for Rheumatoid Arthritis
Abstract Number: 595

Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Abstract Number: 2689

Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity Are Multifactorial in Early Rheumatoid Arthritis
Abstract Number: 1227

Discrepancies Between Registered and Published Primary Outcomes in Randomized Controlled Trials of Rheumatoid Arthritis
Abstract Number: 671

Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Abstract Number: 862

Discriminative Performance of Nasal Endoscopic Findings and History Items in Patients with Granulomatosis with Polyangiitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].